Adult ADHD Treatment Options Compared: Medication, CBT, Coaching and Lifestyle
For adults with ADHD, stimulant medications have the strongest evidence for reducing core symptoms, and a large 2018 network meta-analysis concluded that amphetamines are the preferred first-choice medication for adults in the short term once both benefit and tolerability are weighed. Two non-stimulants, atomoxetine and viloxazine, are FDA-approved for adults and are options for people who should avoid stimulants.
Medication is rarely the whole plan. Cognitive behavioral therapy (CBT) has trial evidence for adults who still have symptoms on medication, while coaching, exercise and sleep changes are useful supports with a thinner evidence base. Many adults end up combining two or three of these.
The options at a glance
| Option | FDA status for adult ADHD | What the evidence shows in adults | Main tradeoffs |
|---|---|---|---|
| Amphetamines (for example mixed amphetamine salts, lisdexamfetamine) | FDA-approved | Largest average effect on clinician-rated symptoms in the 2018 network meta-analysis | Schedule II controlled substance; appetite loss, insomnia, raised heart rate and blood pressure |
| Methylphenidate | FDA-approved (Concerta is labeled for ages 6 to 65) | Better than placebo in adults | Schedule II; side effects similar to amphetamines |
| Atomoxetine | FDA-approved | Better than placebo in adults | Not a controlled substance; dose decisions made over weeks; rare liver injury |
| Viloxazine extended-release | FDA-approved for adults in April 2022 | Approved after the 2018 analysis, so not included in it | Not a controlled substance; Boxed Warning on suicidal thoughts; drug interactions |
| Bupropion | Off-label (approved for depression and seasonal affective disorder) | Better than placebo in adults | Can also treat co-occurring depression; less evidence than stimulants |
| Guanfacine ER, clonidine ER | Off-label in adults; labels based on ages 6 to 17 | Limited adult data | Sleepiness, low blood pressure; must be tapered, not stopped abruptly |
| CBT for adult ADHD | Not applicable | Improved symptoms in medicated adults, maintained at 12 months in one trial | Weekly sessions and practice between them |
| Coaching | Not applicable | Little controlled evidence; field is not standardized | Practical accountability; quality varies widely |
| Exercise | Not applicable | Small short-term effect on core symptoms; long-term evidence mixed | Low risk, good for mood and sleep |
What one adult guideline recommends
The 2018 NICE guideline for England (NG87) sets out an order of treatment for adults, which makes it a useful reference point even outside the UK. It recommends offering medication to adults whose ADHD symptoms still cause significant impairment in at least one area of life after environmental changes have been made and reviewed. It names lisdexamfetamine or methylphenidate as the first-line medicines for adults, and suggests switching to the other after a 6-week trial at an adequate dose that has not given enough benefit. Atomoxetine comes next, for adults who cannot tolerate those two or whose symptoms have not responded to separate 6-week trials of each. NICE advises not offering guanfacine to adults without advice from a specialist (tertiary) ADHD service, and recommends a second opinion or specialist referral if symptoms do not respond to one or more stimulants and one non-stimulant.
For non-medication care, NICE suggests considering it for adults who have made an informed choice not to take medication, have trouble taking it consistently, or found it ineffective or intolerable, and in combination with medication when symptoms still cause significant impairment. At a minimum, that means a structured supportive psychological intervention focused on ADHD with regular follow-up, which may include elements of CBT or a full course. US prescribers work from FDA labels and their own judgment, so a plan here may not follow this order exactly; the guideline is a way to understand the logic, not a rule your prescriber must follow.
Stimulants: methylphenidate and amphetamines
The 2018 network meta-analysis in The Lancet Psychiatry pooled 133 double-blind randomized trials across children, adolescents and adults. In adults, amphetamines, methylphenidate, bupropion and atomoxetine all outperformed placebo on clinician ratings, and in head-to-head comparisons amphetamines came out ahead of methylphenidate, atomoxetine and modafinil. Modafinil was not better than placebo in adults. The authors also noted that there was not enough data to judge longer-term outcomes at 26 and 52 weeks.
Average effects do not predict any one person's response. Some adults do well on methylphenidate and poorly on amphetamine, or the reverse, so a prescriber may try one, adjust the dose, and switch if needed. Doses are usually adjusted step by step; lisdexamfetamine's label, for example, allows changes at about weekly intervals.
The most common side effects in adult and pediatric trials of lisdexamfetamine included decreased appetite, insomnia, dry mouth, anxiety and irritability. Both drug families are Schedule II controlled substances, which affects how prescriptions are written and how often you are seen.
Short-acting, long-acting and how the day is covered
Within each stimulant family there are immediate-release and extended-release versions, and lisdexamfetamine is a prodrug of amphetamine. The practical question is less which molecule is "best" than which version covers the hours you need, such as a workday or an evening of studying, and wears off early enough for sleep. Some adults use a long-acting dose with a short-acting top-up later in the day; others do better on one steady dose. Those are prescriber decisions. Detailed comparisons are in methylphenidate vs amphetamine, Adderall vs Vyvanse and Concerta vs Ritalin vs Focalin.
Non-stimulants approved for adults
Atomoxetine is FDA-approved for ADHD in adults and children 6 and older, and it is not a controlled substance. It works gradually: its label says that if the response at the usual target dose is not optimal after 2 to 4 additional weeks, the dose may then be raised to the maximum. Common adult side effects in trials included constipation, dry mouth, nausea, decreased appetite, dizziness, erectile dysfunction and urinary hesitation, and it should be stopped in anyone who develops jaundice or laboratory signs of liver injury.
Viloxazine extended-release was first approved in April 2021 for children and adolescents, and the FDA approved its use in adults in April 2022. It is now indicated for adults and children 6 and older. Its label carries a Boxed Warning because higher rates of suicidal thoughts and behavior were reported with viloxazine than with placebo in clinical studies, and it cannot be combined with MAO inhibitors or with certain drugs broken down by the liver enzyme CYP1A2. A full medication review matters before starting it.
For how the two approved non-stimulants compare with each other, see Qelbree vs Strattera. The detailed tradeoffs between these and stimulants are in stimulant vs non-stimulant ADHD medication: how to decide.
Off-label medications
Bupropion is FDA-approved for major depressive disorder and the prevention of seasonal affective disorder, not ADHD, so its use for ADHD is off-label. It outperformed placebo in adults in the 2018 analysis, and prescribers sometimes consider it when depression and ADHD occur together.
Guanfacine extended-release and clonidine extended-release are approved for ADHD on the basis of studies in children and adolescents ages 6 to 17, so prescribing them for adult ADHD is off-label. Both labels direct a gradual taper when stopping, to avoid rebound high blood pressure, so the prescriber should plan any discontinuation.
Safety: what the 2023 stimulant warning changed
In May 2023, the FDA required a consistent Boxed Warning across all prescription stimulants describing the risks of misuse, abuse, addiction and overdose. The agency asked prescribers to assess each patient's risk before prescribing and to monitor throughout treatment, and it noted that most people who misuse prescription stimulants get them from family members or peers. Patients are advised never to share their medicine, to store it where others cannot reach it, and to dispose of unused tablets promptly.
Before a stimulant is started, expect questions about heart disease and blood pressure. The lisdexamfetamine label advises avoiding use in people with known structural heart abnormalities, cardiomyopathy, serious arrhythmias or coronary artery disease, monitoring blood pressure and pulse, and screening for risk factors for mania before starting. A history of substance use is not an automatic barrier, but it changes the conversation and may favor a non-stimulant.
CBT built for adult ADHD
CBT for ADHD is different from general talk therapy. It teaches concrete skills: planning and prioritizing, breaking tasks down, managing distraction and procrastination, and challenging the self-critical thinking that years of missed deadlines often leave behind.
In a randomized trial published in JAMA, 86 adults who were already on ADHD medication but still had significant symptoms received 12 individual sessions of either CBT or relaxation training with education. The CBT group had lower symptom scores after treatment, and responders and partial responders kept their gains at 6 and 12 months. This makes CBT a reasonable next step when medication helps but does not close the gap.
The wider evidence is encouraging but not strong. A 2018 Cochrane review of 14 randomized trials with 700 participants found low-quality evidence that CBT-based treatments may help adults with ADHD in the short term, including when added to medication, and that CBT may also ease the depression and anxiety that often come with ADHD. The reviewers pointed to the lack of long-term follow-up data as a key limitation. The practice describes its approach in CBT for adult ADHD in Brooklyn.
Coaching, exercise, sleep and structure
ADHD coaching focuses on goals, routines and accountability rather than diagnosis or emotional work. It can be valuable, but the field is not standardized. A 2026 national survey of 465 US ADHD coaches found that those who started after the COVID-19 pandemic were less likely to hold a health care license or to refer clients to CBT providers or prescribers, and its authors called for clearer training standards and boundaries with psychotherapy. Ask any coach about training, supervision and when they refer on. The distinctions are laid out in coaching, therapy or psychiatry.
Exercise is a sensible addition with modest evidence. A 2026 meta-analysis found that single sessions of exercise had a moderate effect on inhibitory control and a small effect on core symptoms in adults with ADHD, while results for longer exercise programs were mixed and the authors called the evidence preliminary. Sleep, caffeine and alcohol habits, and external structure such as calendars, reminders and checklists, are also part of most plans. The practice's articles on ADHD coping strategies and exercise as ADHD treatment offer practical starting points.
When ADHD comes with something else
Adult ADHD rarely travels alone, and the other condition often shapes the choice of treatment more than the ADHD itself.
| Alongside ADHD | What often changes | Read next |
|---|---|---|
| Anxiety | Which to treat first, and whether a stimulant worsens or eases the anxiety | ADHD and anxiety: which to treat first |
| Depression | Order of treatment; options that may address both | ADHD and depression: treatment order |
| Possible bipolar disorder | Screening for mania risk before a stimulant is started | Bipolar vs ADHD |
| Substance use | Stimulant risk assessment, monitoring and non-stimulant options | Addiction psychiatrist vs general psychiatrist |
| Heart disease or high blood pressure | Cardiac history and blood pressure checks before and during treatment | Heart and blood pressure monitoring |
| Pregnancy or planning pregnancy | Reviewing each medication's risks and benefits with the prescriber | Psychiatric medications during pregnancy |
Hormonal changes across the menstrual cycle and perimenopause can also change how ADHD symptoms feel; the practice's article on ADHD in women covers that, and ADHD and aging looks at later life.
When the first option does not work
A first medication that disappoints is common and does not mean medication cannot help. Before switching, a prescriber will usually look at a few practical questions: whether the dose has been adjusted far enough, whether the timing covers the hours that matter, whether sleep, alcohol or another condition is getting in the way, and whether doses are being missed. If those check out, switching to the other stimulant family, or to a non-stimulant, is a standard next step, and that is also the order NICE describes. The practice's article on when ADHD medication stops working covers the troubleshooting in more detail.
If two or three well-run trials have not helped, it is reasonable to revisit the diagnosis itself and ask whether something else explains the symptoms. Getting a second opinion on your psychiatric medication explains how to ask for one, and neuropsychological testing for ADHD explains when formal testing adds information.
Practical issues that shape the choice
- Supply. The FDA's drug shortage database still listed mixed amphetamine salts tablets as currently in shortage when this article was written. If a pharmacy cannot fill a prescription, talk to the prescriber rather than switching or skipping doses on your own; what to do during a stimulant shortage covers the options.
- Prescription logistics. Stimulants are Schedule II, so prescriptions cannot be refilled in the usual way and visits tend to be more regular. Non-stimulants avoid that.
- Work and school. Treatment and accommodations work together. Workplace accommodations for mental health and college and testing accommodations for ADHD explain how to ask for them.
- Cost. Brand-name medicines can cost more than generics; lowering prescription costs covers ways to bring that down.
What the evidence does not show
An honest comparison has to say where the evidence runs out. The 2018 network meta-analysis found too little data to compare medications at 26 and 52 weeks, so most head-to-head conclusions are about the short term. CBT has trial support, but much of it is rated low quality and long-term follow-up is thin. Coaching has little controlled evidence and no common standard of training. Exercise effects on core symptoms are small and preliminary. None of this means the options do not work; it means a personal trial, measured against your own goals, matters more than any ranking.
How people choose among the options
The best option is the one that fits your health history, your daily demands and your preferences, and that you can sustain. A useful way to frame the decision is to name the two or three problems that cost you the most, such as missed deadlines at work, unpaid bills or arguments at home, and judge every treatment by whether those specific problems improve. Someone who sees you daily can tell you whether the change is visible from outside, which is often more reliable than how focused you feel.
- If you want the largest expected effect and have no heart or substance use concerns, a stimulant trial is the usual first step.
- If you have a history of substance misuse, a household where diversion is a concern, or troublesome anxiety or insomnia on stimulants, discuss a non-stimulant.
- If depression and ADHD occur together, the order of treatment matters, and a prescriber may consider options that address both.
- If medication helps but disorganization and procrastination persist, add CBT or coaching rather than simply raising the dose.
- If you prefer not to take medication, CBT, structure and lifestyle work are legitimate options; expectations should be realistic.
Measuring progress
Self-report alone can mislead in both directions: some people feel sharper on a stimulant without functioning better, and others improve in ways they do not notice. Standard rating scales, repeated at the same points, give a more stable picture, and NICE suggests using symptom and adverse effect rating scales throughout treatment. ADHD rating scales explained shows what the common ones measure. Pair a scale with two or three concrete targets from your own life, and review both at each follow-up.
Questions to ask your prescriber
- Why this medication first, and what would make you switch?
- Which formulation fits my day, and when should it wear off so I can sleep?
- What heart or blood pressure checks do I need before and during treatment?
- How will we measure improvement: rating scales, specific tasks, feedback from someone close to me?
- What should I do if I miss doses, travel, or cannot get my prescription filled?
- Which non-medication supports would add the most for my situation?
Whatever you choose, agree on how you will measure progress, and do not start, stop or change a medication without your prescriber. Some ADHD medicines carry warnings about mood changes and suicidal thoughts, so report any new or worsening low mood promptly. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.
How the practice approaches adult ADHD treatment
After its ADHD assessment, the practice builds a personalized plan that may include lifestyle changes, nutrition and supplements, psychotherapy, executive-function coaching and medication when appropriate, delivered by its therapy, coaching or prescriber team. Its clinicians have written three published ADHD workbooks. The assessment itself uses a structured clinical interview, standardized rating scales that support but do not replace clinical diagnosis, and collateral history from someone who knows you well. The ADHD workbooks and resources page lists further reading. More detail is on the adult ADHD treatment page, and the evaluation itself is described in the practice's ADHD assessment: steps and preparation. For what follow-up visits involve once medication starts, see ongoing medication management, and for the bigger picture, the guide to choosing psychiatric care.
Frequently asked questions
Is medication or therapy better for adult ADHD?
On average, medication has the larger effect on core symptoms. CBT adds benefit for adults who still struggle on medication, and some people prefer to start without medication. Many adults use both.
Are non-stimulants weaker than stimulants?
On average, yes. In school-age children, the AAP describes an effect size of about 1.0 for stimulants and 0.7 for non-stimulants. Individuals vary, and a non-stimulant can be the better choice when stimulants are unsafe or poorly tolerated.
Can I get a stimulant if I have a history of substance use?
Possibly, but it calls for a careful discussion with a prescriber about risk, monitoring and alternatives. Non-stimulants such as atomoxetine and viloxazine are not controlled substances and are often considered in this situation.
Is ADHD coaching covered by insurance?
Coaching is not psychotherapy or medical treatment, so check with your plan before assuming it is covered. Psychotherapy, including CBT, is a health care service and may be eligible for out-of-network reimbursement if you have those benefits.
How long does it take to find the right ADHD medication?
It varies. Stimulant doses are often adjusted over several weeks, and non-stimulants take longer to judge. Expect a few follow-up visits before settling on a dose, and tell your prescriber about side effects rather than adjusting on your own.
What should happen if my first ADHD medication does not help?
Your prescriber will usually check the dose, timing, sleep and other conditions first, then consider switching to the other stimulant family or a non-stimulant. The NICE adult guideline describes switching after a 6-week trial at an adequate dose. Do not switch or stop on your own.
Is lisdexamfetamine (Vyvanse) the same as Adderall?
Both are amphetamine-based stimulants, but lisdexamfetamine is a prodrug that the body converts to its active form, and the two are different products with different labels. Your prescriber can explain which suits your day.
Can I rely on lifestyle changes alone?
Some adults with milder symptoms choose to, and NICE lists an informed choice not to take medication as a reason to consider non-medication treatment. The evidence for lifestyle approaches on their own is limited and mostly short term, so agree with your clinician on how you will measure progress.
Sources
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry (Cortese S et al.), 2018. pubmed.ncbi.nlm.nih.gov
- Strattera (atomoxetine) prescribing information. Eli Lilly and Company / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
- Qelbree (viloxazine extended-release capsules) prescribing information. Supernus Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
- Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA (Safren SA et al.), 2010. pubmed.ncbi.nlm.nih.gov
- Adderall XR (mixed amphetamine salts extended-release) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
- Vyvanse (lisdexamfetamine dimesylate) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
- Concerta (methylphenidate HCl extended-release tablets) prescribing information. Janssen Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
- Drugs@FDA: Qelbree (viloxazine hydrochloride), NDA 211964. U.S. Food and Drug Administration, 2022. accessdata.fda.gov
- Wellbutrin XL (bupropion HCl extended-release) prescribing information. Bausch Health / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
- Intuniv (guanfacine extended-release tablets) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
- Clonidine hydrochloride extended-release tablets prescribing information. Somerset Therapeutics / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
- ADHD coaching since the COVID-19 pandemic: Is there a new wave of ADHD coaches?. Frontiers in Psychiatry (Graham ED et al.), 2026. doi.org
- The effects of acute and chronic exercise on executive functions and core symptoms in adults with ADHD: A systematic review and meta-analysis. Psychology of Sport and Exercise (Xu S, Zhao C, Hu L), 2026. doi.org
- FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. U.S. Food and Drug Administration (Drug Safety Communication), 2023. fda.gov
- Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. American Academy of Pediatrics, Pediatrics 144(4):e20192528, 2019. pmc.ncbi.nlm.nih.gov
- Attention deficit hyperactivity disorder: diagnosis and management (NG87), Recommendations. National Institute for Health and Care Excellence (NICE), 2019. nice.org.uk
- FDA Drug Shortages: Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate Tablets. U.S. Food and Drug Administration, 2026. accessdata.fda.gov
- Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews (Lopez PL et al.), 2018. pubmed.ncbi.nlm.nih.gov
Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel